Drug Profile
Research programme: kidney disorder therapeutics - Celtic Biotech Iowa
Alternative Names: Cardiotoxin-based therapeutics - CelticLatest Information Update: 23 Aug 2023
Price :
$50
*
At a glance
- Originator Unknown
- Developer Celtic Biotech Iowa
- Class Cobra cardiotoxin proteins; Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Kidney disorders
Most Recent Events
- 23 Aug 2023 Discontinued - Preclinical for Kidney disorders in USA (unspecified route) before August 2023 (Celtic Biotech Iowa pipeline, August 2023)
- 28 Apr 2019 No recent reports of development identified for preclinical development in Kidney-disorders in USA